Potential Benefit of Add-on Δ9-Tetrahydrocannabinol in Pediatric Drug-Resistant Epilepsy- A Case Series

Cambridge Core- Canadian Journal of Neurological Sciences>Volume 49 Issue 4
2022
Magda Nowicki Open the ORCID record for Magda Nowicki[Opens in a new window] , Sandrine Bourgeois-Tardif Open the ORCID record for Sandrine Bourgeois-Tardif[Opens in a new window] , Patrick L. Diaz Open the ORCID record for Patrick L. Diaz[Opens in a new window] , Francois Olivier Hebert Open the ORCID record for Francois Olivier Hebert[Opens in a new window] , Nathalie T. Sanon , Pierre-Olivier Champagne , Philippe Major , Erick Sell , Jonathan Bitton , Evan Lewis Open the ORCID record for Evan Lewis[Opens in a new window] and Alexander G. Weil

Abstract:

We present five cases of pediatric drug-resistant epilepsy (DRE) that failed management using high cannabidiol (CBD) doses, but had significant reduction in seizure frequency with reintroduction or increasing doses of tetrahydrocannabinol (THC). There is growing evidence supporting the use of whole-plant CBD-rich extracts (containing THC and other cannabinoids) in the treatment of pediatric DRE. Based on our experiences and reports in the literature, we propose that, in patients who fail management with an initial trial of high-dose CBD-focused therapy, there may be a role for add-on THC-focused formulations.

Open Full Article

This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.

Search the Research Library

  • Conditions

  • Research Keywords

  • Search Text

  • Reset